Laboratories / 22.05.2025
Why OSHA Compliance Certification Supports Safer Medical and Research Environments
[caption id="attachment_68652" align="aligncenter" width="500"]
Photo by Artem Podrez[/caption]
In clinical and research settings, precision and control are everything. Whether conducting patient care, handling biological specimens or operating within a sterile lab environment, every person involved must operate with safety in mind. While much attention is often given to technical procedures and scientific outcomes, the foundation that makes these environments functional is a shared understanding of workplace safety. This is where an OSHA compliance certification becomes essential.
Medical and research facilities are not immune to hazards. Everyday, professionals work with chemical agents, compressed gases, sharps lab equipment and occasionally volatile substances. These environments demand more than professional skill; they require a framework that reinforces how to prevent incidents before they occur. OSHA, the Occupational Safety and Health Administration, provides exactly that framework through its compliance standards and training programs.
Photo by Artem Podrez[/caption]
In clinical and research settings, precision and control are everything. Whether conducting patient care, handling biological specimens or operating within a sterile lab environment, every person involved must operate with safety in mind. While much attention is often given to technical procedures and scientific outcomes, the foundation that makes these environments functional is a shared understanding of workplace safety. This is where an OSHA compliance certification becomes essential.
Medical and research facilities are not immune to hazards. Everyday, professionals work with chemical agents, compressed gases, sharps lab equipment and occasionally volatile substances. These environments demand more than professional skill; they require a framework that reinforces how to prevent incidents before they occur. OSHA, the Occupational Safety and Health Administration, provides exactly that framework through its compliance standards and training programs.
Dr. Steenson[/caption]
Dr. Simon Steenson PhD
Postdoctoral Research Associate
Department of Nutritional Sciences
King’s College London
MedicalResearch.com: What is the background for this study?
Response: Chronic constipation is something that can be embarrassing, but it affects 1 in 10 people globally. It has a big impact on people’s quality of life and treating constipation has substantial costs for the healthcare system. Dried fruits are recommended for managing constipation, but there are very few studies that have actually tested whether following this advice is helpful. To fill this gap in our knowledge, we completed the largest clinical trial to date to see whether dried fruits and fruit juices could benefit constipation symptoms.
Dr. Corley[/caption]
Douglas Corley, MD, PhD
Chief Research Officer, The Permanente Medical Group
Kaiser Permanente, Northern California
MedicalResearch.com: What is the background for this study?
Response: Kaiser Permanente Northern California (KPNC) is an integrated health care system that designs and implements population-based programs that support cancer prevention and early detection. In 2006, KPNC began to implement a comprehensive colorectal cancer screening program with the goal of increasing member screening rates, preventing colorectal cancer through polyp removal, and reducing cancer mortality. The initiative identifies whether screening-eligible KPNC members are up to date with their colorectal cancer screening test by either a colonoscopy or by stool-based tests, such as a fecal immunochemical testing (FIT) kit. If they are not up to date with screening, it mails them a FIT kit for at-home testing. Members can also choose other options for colorectal cancer screening, such as a colonoscopy, through their physician.
Dr. Klonoff[/caption]
Parita K. Ray[/caption]
Prof. El GHOCH[/caption]
MedicalResearch.com Interview with:
Prof. Marwan EL GHOCH
Dr. Bradshaw[/caption]
Catriona Bradshaw MMBS(Hons), PhD, FAChSHM, FAHMS
Professor (Research), Head of Research Translation and Mentorship
and of The Genital Microbiota and Mycoplasma Group Melbourne
School of Translational Medicine, Monash University and Alfred Hospital
Principal Research Fellow at the Burnet Institute
MedicalResearch.com: What is the background for this study?
Response: One in three women globally have bacterial vaginosis (BV), a condition that causes a malodourous discharge, and associated with serious gynaecologic and obstetric sequelae (including miscarriage and preterm birth) and increases the risk sexually transmitted infections (STIs) and HIV. Women with symptoms are treated with broad-spectrum antibiotics, however, over 50% of women experience BV recurrence within 3-6 months. The recurrence rate is even higher at 60-80% among women with an ongoing regular partner. Current practice is to simply retreat women experiencing BV recurrence with the same antibiotics, which leaves them (and clinicians) frustrated and distressed.
We and others have accumulated a body of evidence to show that BV has the profile of an STI. BV-associated bacteria are detected in men in the distal urethra and on penile-skin, and couples share these organisms. However, to date, has not been recommended for BV as it is for other STIs. This is largely because men do not usually have any symptoms, and past partner-treatment trials in the 1980s and 1990s, which only used oral antibiotics for men, failed to prevent BV recurrence, which was taken as conclusive evidence against sexual transmission. Reviews of these trials have since identified their limitations.
Given the evidence of male carriage of BV-associated bacteria at two genital sites, we hypothesised that both sites needed to be targeted with antimicrobial therapy to prevent re-infection post-treatment. The aim of our study was to assess if male partner-treatment concurrently with female treatment using a combination of oral and topical antibiotics for the first time, would decrease BV recurrence over 12 weeks compared to the current standard practice of treating women only.
Dr. Mzoughi[/caption]
Slim Mzoughi, PhD